Luye Pharma Group (FRA:LUP) Long-Term Debt : €350.1 Mil (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Luye Pharma Group Long-Term Debt?

Luye Pharma Group's Long-Term Debt for the quarter that ended in Jun. 2024 was €350.1 Mil.

Luye Pharma Group's quarterly Long-Term Debt increased from Jun. 2023 (€268.0 Mil) to Dec. 2023 (€407.9 Mil) but then declined from Dec. 2023 (€407.9 Mil) to Jun. 2024 (€350.1 Mil).

Luye Pharma Group's annual Long-Term Debt declined from Dec. 2021 (€584.7 Mil) to Dec. 2022 (€303.5 Mil) but then increased from Dec. 2022 (€303.5 Mil) to Dec. 2023 (€407.9 Mil).

Luye Pharma Group Long-Term Debt Historical Data

The historical data trend for Luye Pharma Group's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luye Pharma Group Long-Term Debt Chart

Luye Pharma Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

577.18

543.90

584.74

303.51

407.89

Luye Pharma Group Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Long-Term Debt	Get a 7-Day Free Trial															531.02	303.51	267.96	407.89	350.13

Luye Pharma Group (FRA:LUP) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Luye Pharma Group Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Luye Pharma Group's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Luye Pharma Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luye Pharma Group Ltd (FRA:LUP) » Definitions » Long-Term Debt

Traded in Other Exchanges

02186:Hong Kong

Address

Hongqiao Road 1438, 22/F, Gubei International Fortune Center II, Changning District, Shanghai, CHN, 264003

Website

https://www.luye.cn

Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, Cardiovascular system drugs, Alimentary tract and metabolism drugs and Central nervous system drugs. It derives maximum revenue from the sale of Oncology drugs.

Luye Pharma Group Headlines

No Headlines